Ensysce Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENSC research report →
Price Chart
About the company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology.
- CEO
- D. Lynn Kirkpatrick
- IPO
- 2018
- Employees
- 9
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on ENSC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.81M
- P/E
- -0.14
- PEG
- 0.01
- P/S
- 4.99
- P/B
- -6.30
- EV/EBITDA
- -0.42
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1087.47%
- Net Margin
- -1084.23%
- ROE
- -1532.33%
- ROIC
- 1385.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-10,240,946
- Net Income
- $-10,175,700-27.4%
- EPS
- $-3.98+12.9%
- OCF Growth
- -4.0%
- FCF Growth
- -5.7%
- 52W High
- $2.75
- 52W Low
- $0.23
- 50D MA
- $0.31
- 200D MA
- $0.70
- Beta
- 0.90
- RSI (14)
- 54
- Avg Volume
- 14.85M
No earnings-call transcripts are available for ENSC yet.
- Free Float
- 95.6%
- Shares Outstanding
- 15.37M
- Float Shares
- 14.68M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Covington Capital Management | 100 | 0 |
Held by 4 ETFs
Biggest fund positions in ENSC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 7, 26 | GOWER BOB G | buy | 400,000 |
| Apr 23, 26 | GOWER BOB G | buy | 508,614 |
| Apr 23, 26 | GOWER BOB G | other | 254,307 |
| Aug 5, 26 | Morrison James William | other | 154,821,000 |
| Mar 2, 23 | GOWER BOB G | buy | 90,287 |
| Mar 1, 23 | GOWER BOB G | buy | 270,000 |
| Feb 28, 23 | GOWER BOB G | buy | 109,300 |
| Dec 9, 22 | GOWER BOB G | buy | 357,143 |
| Dec 9, 22 | GOWER BOB G | other | 714,286 |
| Jun 23, 22 | Chang William H | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENSC coverage
Recent articles, reports, and earnings notes.
No research on ENSC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENSC report →Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
accessnewswire.com · Aug 20
Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
seekingalpha.com · Aug 18
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
accessnewswire.com · Aug 13
Ensysce Biosciences (NASDAQ:ENSC) versus CannAmerica Brands (OTCMKTS:CNNXF) Head to Head Review
defenseworld.net · Aug 13
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
accessnewswire.com · Aug 6
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
accessnewswire.com · Jul 14
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
accessnewswire.com · Jun 26
Ensysce Biosciences Reports First Quarter 2026 Financial Results
accessnewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.